Literature DB >> 24706162

Neurofibromatosis type 1 (NF1) with an unusually severe phenotype due to digeny for NF1 and ryanodine receptor 1 associated myopathy.

Florence Martin1, Veronika Kana, Andrea Capone Mori, Dirk Fischer, Nicolas Parkin, Eugen Boltshauser, Elisabeth Jane Rushing, Andrea Klein.   

Abstract

UNLABELLED: We describe a 5-year-old girl with marked hypotonia, poor feeding and reduced facial expression since birth. Congenital myopathy was suspected; muscle biopsy showed unspecific type 1 fibre predominance. The possibility of a ryanodine receptor 1 gene (RYR1)-associated myopathy was considered, but not further investigated. At the age of 2 years, she presented with exophthalmos. Brain MRI revealed optic pathway glioma. On clinical examination, she had six café-au-lait spots, thus fulfilling the diagnostic criteria for neurofibromatosis type 1 (NF1). The hypotonia was then attributed to NF1. At the age of 3 years, she developed scoliosis and had an unusually severe motor delay for NF1, as she was not able to walk independently. Dual pathology was suspected, and muscle MRI showed the typical pattern for RYR1-related myopathy. This was genetically confirmed with the discovery of two heterozygous mutations.
CONCLUSION: NF1 is one of the most frequent genetic diseases in children. RYR1-related myopathy is one of the most frequent causes of congenital myopathy. The combination of these two pathologies has not yet been described. In cases of unusual presentations or clinical course, the possibility of genetic "double trouble" should be considered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24706162     DOI: 10.1007/s00431-014-2314-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Central core myopathy with RYR1 mutation masks 5q spinal muscular atrophy.

Authors:  R Pandey; S Chandratre; A Roberts; J S M Dwyer; C Sewry; R Quinlivan
Journal:  Eur J Paediatr Neurol       Date:  2010-05-08       Impact factor: 3.140

2.  Mental, motor, and language development of toddlers with neurofibromatosis type 1.

Authors:  Jennifer Lorenzo; Belinda Barton; Maria T Acosta; Kathryn North
Journal:  J Pediatr       Date:  2010-11-20       Impact factor: 4.406

3.  Applications of MRI in muscle diseases.

Authors:  Pierre G Carlier; Eugenio Mercuri; Volker Straub
Journal:  Neuromuscul Disord       Date:  2012-10-01       Impact factor: 4.296

4.  Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies.

Authors:  Andrea Klein; Suzanne Lillis; Iulia Munteanu; Mariacristina Scoto; Haiyan Zhou; Ros Quinlivan; Volker Straub; Adnan Y Manzur; Helen Roper; Pierre-Yves Jeannet; Wojtek Rakowicz; David Hilton Jones; Uffe Birk Jensen; Elizabeth Wraige; Natalie Trump; Ulrike Schara; Hanns Lochmuller; Anna Sarkozy; Helen Kingston; Fiona Norwood; Maxwell Damian; Janbernd Kirschner; Cheryl Longman; Mark Roberts; Michaela Auer-Grumbach; Imelda Hughes; Kate Bushby; Caroline Sewry; Stephanie Robb; Stephen Abbs; Heinz Jungbluth; Francesco Muntoni
Journal:  Hum Mutat       Date:  2012-04-04       Impact factor: 4.878

5.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

6.  Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions.

Authors:  V-F Mautner; L Kluwe; R E Friedrich; A C Roehl; S Bammert; J Högel; H Spöri; D N Cooper; H Kehrer-Sawatzki
Journal:  J Med Genet       Date:  2010-06-12       Impact factor: 6.318

Review 7.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.

Authors:  Rosalie E Ferner; Susan M Huson; Nick Thomas; Celia Moss; Harry Willshaw; D Gareth Evans; Meena Upadhyaya; Richard Towers; Michael Gleeson; Christine Steiger; Amanda Kirby
Journal:  J Med Genet       Date:  2006-11-14       Impact factor: 6.318

8.  Becker's muscular dystrophy aggravating facioscapulohumeral muscular dystrophy--double trouble as an explanation for an atypical phenotype.

Authors:  S Rudnik-Schöneborn; J Weis; W Kress; M Häusler; K Zerres
Journal:  Neuromuscul Disord       Date:  2008-08-05       Impact factor: 4.296

9.  A cost savings approach to SPRED1 mutational analysis in individuals at risk for neurofibromatosis type 1.

Authors:  Talia M Muram; David A Stevenson; Sarah Watts-Justice; David H Viskochil; John C Carey; Rong Mao; Brian Jackson
Journal:  Am J Med Genet A       Date:  2013-02-07       Impact factor: 2.802

10.  Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further evidence for "double trouble" overlapping syndromes.

Authors:  Giulia Ricci; Isabella Scionti; Greta Alì; Leda Volpi; Virna Zampa; Marina Fanin; Corrado Angelini; Luisa Politano; Rossella Tupler; Gabriele Siciliano
Journal:  Neuromuscul Disord       Date:  2012-01-14       Impact factor: 4.296

View more
  2 in total

Review 1.  Skeletal muscle and motor deficits in Neurofibromatosis Type 1.

Authors:  M A Summers; K G Quinlan; J M Payne; D G Little; K N North; A Schindeler
Journal:  J Musculoskelet Neuronal Interact       Date:  2015-06       Impact factor: 2.041

2.  Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study.

Authors:  Aurora Fusto; Denise Cassandrini; Claudio Bruno; Elena Pegoraro; Chiara Fiorillo; Valentina Codemo; Guja Astrea; Adele D'Amico; Lorenzo Maggi; Francesca Magri; Marika Pane; Giorgio Tasca; Daniele Sabbatini; Luca Bello; Roberta Battini; Pia Bernasconi; Fabiana Fattori; Enrico Silvio Bertini; Giacomo Comi; Sonia Messina; Tiziana Mongini; Isabella Moroni; Chiara Panicucci; Angela Berardinelli; Alice Donati; Vincenzo Nigro; Antonella Pini; Melania Giannotta; Claudia Dosi; Enzo Ricci; Eugenio Mercuri; Giovanni Minervini; Silvio Tosatto; Filippo Santorelli
Journal:  Acta Neuropathol Commun       Date:  2022-04-15       Impact factor: 7.578

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.